Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: A retrospective, population-based cohort study

Pharmacotherapy

Volumn 34, Issue 4, 2014, Pages 336-349

  Kaye, James A ^a   Castellsague, Jordi ^a   Bui, Christine L ^a   Calingaert, Brian ^a   McQuay, Lisa J ^a   Riera Guardia, Nuria ^a   Saltus, Catherine W ^a   Quinlan, Scott ^b   Holick, Crystal N ^b   Wahl, Peter M ^b   Suzart, Kiliana ^c   Rothman, Kenneth J ^a   Wallander, Mari Ann ^c   Perez Gutthann, Susana ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b HEALTHCORE INC   (United States)

^c BAYER PHARMA AG   (Germany)

Author keywords

amoxicillin; antiinfective agents; drug induced liver injury; epidemiology; fluoroquinolones; levofloxacin; moxifloxacin; telithromycin

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CEFUROXIME; CLARITHROMYCIN; DOXYCYCLINE; LEVOFLOXACIN; MOXIFLOXACIN; TELITHROMYCIN; QUINOLONE DERIVATIVE;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; DRUG USE; EMERGENCY TREATMENT; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; LIVER CELL DAMAGE; LIVER FAILURE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; VERY ELDERLY; ADOLESCENT; DRUG-INDUCED LIVER INJURY; MIDDLE AGED; RISK;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COHORT STUDIES; DRUG-INDUCED LIVER INJURY; FEMALE; FLUOROQUINOLONES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK;

EID: 84898919916     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1367     Document Type: Article

References (40)

1. García Rodríguez LA, Pérez Gutthann S, Walker AM, Lueck L,. The role of non-steroidal anti-inflammatory drugs in acute liver injury. BMJ 1992; 305: 865-8.
2. Maggini M, Raschetti R, Agostinis L, Cattaruzzi C, Troncon MG, Simon G,. Use of amoxicillin and amoxicillin-clavulanic acid and hospitalization for acute liver injury. Ann Ist Super Sanita 1999; 35: 429-33.
3. García Rodríguez LA, Duque A, Castellsague J, Pérez-Gutthann S, Stricker BH,. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999; 48: 847-52.
4. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-5.
5. Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M,. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003; 327: 18-22.
6. de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA,. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58: 71-80.
7. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-21.
8. Andrade RJ, Tulkens PM,. Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother 2011; 66: 1431-46.
9. Derby LE, Gutthann SP, Jick H, Dean AD,. Liver disorders in patients receiving chlorpromazine or isoniazid. Pharmacotherapy 1993; 13: 353-8.
10. Food and Drug Administration. NDA 21-144 Advisory Committee briefing package for Ketek. Appendix H: epidemiology tables. 2006. Available from http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4266b1-01-11-Ketek- appendix-h.pdf. Accessed March 12, 2012.
11. Food and Drug Administration. Letter to Bayer Pharmaceuticals Corporation regarding NDA 21-085/S-036 and NDA 21-277/S-030. May 31, 2007. Available from http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2007/021085s036, 021277s030ltr.pdf. Accessed March 12, 2012.
12. European Medicines Agency. European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines (press release). July 24, 2008. Available from http://www.ema.europa.eu/docs/en-GB/document- library/Press-release/2010/08/WC500095423.pdf. Accessed March 12, 2012.
13. European Medicines Agency. Annex II: scientific conclusions and grounds for amendment of the summary of product characteristics and package leaflet [for moxifloxacin]. 2008. Available from http://ec.europa.eu/health/documents/ community-register/2008/2008071446252/anx-46252-en.pdf. Accessed March 12, 2012.
14. European Medicines Agency. Annex III: amendments to summary of product characteristics and package leaflet (relevant sections only). 2008. Available from http://ec.europa.eu/health/documents/community-register/2008/2008071446252/ anx-46252-en.pdf. Accessed March 12, 2012.
15. Bayer Pharma AG. European summary of product characteristics. Avelox 400 mg film-coated tablets (moxifloxacin hydrochloride). Text revised April 2012. Available from http://www.medicines.org.uk/emc/medicine/11841/SPC/ avelox%20400%20 mg%20film-coated%20tablets/. Accessed March 12, 2012.
16. Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010; 303: 1401-9.
17. Velentgas P, Amato AA, Bohn RL, et al. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf 2012; 21: 1350-8.
18. Stephenson JJ, Quimbo RA, Gutierrez B,. Subacute lack of asthma control as a predictor of subsequent acute asthma exacerbation in a managed care population. Am J Manag Care 2010; 16: 108-14.
19. Lo Re V 3rd, Haynes K, Ming EE, et al. Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. Pharmacoepidemiol Drug Saf 2012; 21: 1202-15.
20. Wahl PM, Rodgers K, Schneeweiss S, et al. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf 2010; 19: 596-603.
21. Platt R, Wilson M, Chan KA, Benner JS, Marchibroda J, McClellan M,. The new Sentinel Network-improving the evidence of medical-product safety. N Engl J Med 2009; 361: 645-7.
22. Bénichou C,. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11: 272-6.
23. Navarro VJ, Senior JR,. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731-9.
24. Temple R,. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 15: 241-3.
25. FDA Working Group. CDER-PhRMA-AASLD Conference 2000: clinical white paper on drug-induced hepatotoxicity. November 2000. Available from http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/ucm091457.pdf. Accessed March 12, 2012.
26. Polson J, Lee WM,. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41: 1179-97.
27. Lee WM, Stravitz RT, Larson AM,. Introduction to the revised American Association for the Study of Liver Diseases position paper on acute liver failure 2011. Hepatology 2012; 55: 965-7.
28. Kaye JA, Castellsague J, Bui CL, et al. Case screening and validation in a population-based study of antimicrobial use and acute liver injury (abstract no. 12). Pharmacoepidemiol Drug Saf 2011; 20: S5.
29. Rothman KJ, Greenland S, Lash TL,. Case-control studies. In:, Rothman KJ, Greenland S, Lash TL, eds. Modern epidemiology, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2008: 111-27.
30. Deyo RA, Cherkin DC, Ciol MA,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-9.
31. International Society for Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2008; 17: 200-8.
32. Food and Drug Administration. Guidance for industry and FDA staff. Best practices for conducting and reporting pharmacoepidemiologic safety studies using electronic healthcare data sets (draft guidance). February 2011. Available from http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM243537.pdf. Accessed March 12, 2012.
33. Perez Gutthann S, García Rodríguez LA,. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology 1993; 4: 496-501.
34. Van Bambeke F, Tulkens PM,. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32: 359-78.
35. De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bjornsson E,. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006; 24: 1187-95.
36. Orman ES, Conjeevaram HS, Vuppalanchi R, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 2011; 9: 517-523.e3.
37. García Rodríguez LA, Stricker BH, Zimmerman HJ,. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996; 156: 1327-32.
38. ® (telithromycin) dear healthcare professional letter. March 2011. Available from http://www.fda.gov/downloads/ Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM154544. pdf. Accessed March 12, 2012.
39. Rothman KJ, Poole C,. A strengthening programme for weak associations. Int J Epidemiol 1988; 17: 955-9.
40. Russmann S, Kaye JA, Jick SS, Jick H,. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol 2005; 60: 76-82.